Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
How asset supply and demand is shaping biopharmaceutical dealmaking
8 years ago
Biopharmaceutical Dealmakers’ Intentions in 2017: Influences and Hot Spots
8 years ago
CVS Leads Trend Toward Less Expensive Neutropenia Treatments
9 years ago
First page
Previous page
8
9
10
11
